New data for presentation at ASCO 2008

Not for distribution to US Media

Issued – Tuesday 22 April 2008, London, UK & Philadelphia, US

GlaxoSmithKline Oncology will present a wide range of new data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago starting Friday, May 30^th. The data cover a variety of therapies, experimental medicines and immunotherapeutics for the treatment and supportive care of cancer patients. At this year’s ASCO meeting, GSK Oncology will present data that demonstrate trends in cancer research, including the combination of targeted therapies and a focus on oral treatment options.

GSK will make data presentations for Tykerb^®/Tyverb^® (lapatinib), which is approved in more than 20 countries, including the US. The US indication is in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2/ErbB2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

GSK will also present new data for Hycamtin^® (topetecan HCl) and for several investigational medicines, including the oral multikinase angiogenesis inhibitor, Armala™ (pazopanib); the neurokinin-1 receptor antagonist, Rezonic™/Zunrisa™ (casopitant); the oxidative stress inducer, elesclomol; and the antigen-specific cancer immunotherapeutic, MAGE-A3 ASCI.

Highlights of the GSK Oncology data to be presented at ASCO include:

Breast Cancer

• A randomised study of lapatinib in combination with trastuzumab vs. lapatinib monotherapy in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [Phase III]
• • Dr. Joyce O'Shaughnessy, Baylor-Sammons Cancer Center, Texas Oncology, PA, US Oncology, Dallas, TX, abstract # 1015, oral presentation, Sunday, June 01, 2008, 9:15 am – 9:30 am, E-Hall D1
• Randomised study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2+ advanced or metastatic breast cancer [Phase II]
• • Dr. Dennis Slamon, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, abstract # 1016, oral presentation, Sunday, June 01, 2008, 9:30 am – 9:45 am, E-Hall D1

• A phase II evaluation of lapatinib and bevacizumab in HER2+ metastatic breast cancer (MBC)
• • Dr. Hope Rugo, UCSF Comprehensive Cancer Center, San Francisco, CA, abstract # 1042, poster discussion, Tuesday, June 3, 11:00 am – 12:00 pm, E Hall 354a; (poster presentation 8:00 am – 12:00 pm, E Hall 450B)

• Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): final results of the expanded HER2+ cohort in EGF103009 [Phase II]
  • Dr. Bella Kaufman, The Chaim Sheba Medical Center, Tel Hashomer, Israel, abstract # 636, poster presentation, Monday, June 02, 2008, 2 pm – 6 pm, S-Hall A1

Melanoma

• Phase II trial of elesclomol* (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy
• • Dr. David Lawson, Emory University, abstract # 9036, poster presentation, Saturday, May 31, 2008, 2 pm – 6 pm, S-Hall A1

• Immunisation with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomised open-label phase II study of the EORTC Melanoma Group (16032-18031)
  • Dr. Wim Kruit, Erasmus Medical Center, Rotterdam, Netherlands, abstract # 9065, poster presentation, Saturday, May 31, 2008, 2 pm – 6 pm, S-Hall A1

Chemotherapy-Induced Nausea and Vomiting (CINV)

• Phase III results of a novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
• • Dr. Steven Grunberg, Vermont Cancer Center at University of Vermont and Fletcher Allen Health Care, abstract # 9540, poster discussion, Friday, May 30, 5 pm – 6 pm, S 406 Vista Room; (poster presentation 2 pm – 6 pm, S403)

• Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
• • Dr. Jorn Herrstedt, Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Copenhagen, Denmark, abstract # 9549, poster presentation, Saturday, May 31, 2 pm – 6 pm, S Hall A1

Renal Cell Cancer (RCC)

• Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor
  • Dr. Thomas E. Hutson, Baylor-Sammons/Texas Oncology PA, Dallas, TX, abstract # 5046, poster discussion, Sunday, June 01, 2008, 11 am – 12 pm, W375a (poster presentation 8:00 am – 12:00 pm; W375e Lobby)

Non-Small Cell Lung Cancer

• Preoperative treatment with pazopanib (GW786034) a multikinase angiogenesis inhibitor in early stage non-small cell lung cancer (NSCLC): a proof-of-concept phase II study
  • Dr. Nasser Altorki, Weill Medical College of Cornell University, abstract # 7557, poster presentation, Sunday, June 01, 2008, 2 pm – 6 pm, S-Hall A1

Small Cell Lung Cancer

• Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease - small cell lung cancer (ED-SCLC): final results of a randomised phase III trial
  • Dr. David Heigener, Krankenhaus Grosshansdorf, Grosshansdorf, Germany, abstract # 7513, oral presentation, Sunday, June 01, 2008, 10:15 am – 10:30 am, W375e (oral session 8:00 am – 11:00 am; W375e)

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK’s revolutionary ‘bench to bedside’ approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com .

Notes to editors:

Tyverb^®, Tykerb^® and Hycamtin^® are trademarks of the GlaxoSmithKline group of companies.

Tykerb^® is the brand name used for lapatinib in the United States and certain other countries.

Tyverb^® is the brand name used for lapatinib in Switzerland and is the proposed trade name in the European Union, pending regulatory approval.

Armala™, Rezonic™ and Zunrisa™ are trademarks of the GlaxoSmithKline group of companies.

*Elesclomol is being developed under a global collaboration agreement between Synta Pharmaceuticals and GSK.

Enquiries:

 

UK Media enquiries:	Philip Thomson	(020) 8047 5502
	Alice Hunt	(020) 8047 5502
	Gwenan White	(020) 8047 5502
European Analyst/Investor enquiries:	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543
	Gary Davies	(020) 8047 5503

For on-site contact at ASCO 30 May – 3 June 2008:

US Media Only	Sarah Alspach Tykerb, Armala & Elesclomol	(215) 287 6354
	Jeff Mclaughlin Rezonic	(215) 589 3774
Global Media	Gregory Clarke Tykerb/Tyverg, Armala & Elesclomol	(317) 694 3545
	Garry Daniels MAGE-A3 ASCI	(32) 477 03 16 13
European Media	Sonja Luz	+44 792 056 8625